Journal article
Assessment of SiCaP-30 in a Rabbit Posterolateral Fusion Model with Concurrent Chemotherapy
The Iowa orthopaedic journal, Vol.35, pp.140-146
2015
PMCID: PMC4492144
PMID: 26361457
Appears in Diamond Open Access
Abstract
Chemotherapy derivatives of the rabbit posterolateral fusion model are considered a challenging environment in which to test bone graft materials. The purpose of this study was to determine the performance characteristics of SiCaP-30 as a bone graft substitute relative to autograft (iliac crest bone graft [ICBG]), Actifuse ABX and β-Tricalcium Phosphate-Bioactive Glass-Type I Collagen (βTCP-BG) in a rabbit posterolateral spine fusion model with concurrent chemotherapy treatment This was a randomized, controlled study in a laboratory setting with blinded assessment of fusion by manual palpation and flexibility testing. Sixty rabbits were entered into the study with 45 used for analysis. Chemotherapeutic agents, doxorubicin and cis-platin (2.5 mg/kg), were administered one week prior to surgery, and one, two and three weeks post surgery. Bilateral posterolateral lumbar intertransverse process fusions were performed at L5-L6. The lateral two thirds of the transverse processes were decorticated and covered with 3cc/side of one of the following graft materials: autologous ICBG, Actifuse ABX (ApaTech Ltd, UK), Vitoss BA (Orthovita, USA) or SiCaP-30 (ApaTech Ltd., UK). Animals were euthanized 12 weeks post surgery. The ICBG group had a 45% (5/11) manual palpation fusion rate and correlated with motion analysis fusion results of 36% (4/11). The Actifuse ABX group had a 33% (4/12) manual palpation fusion rate and a motion analysis fusion rate of 25% (3/12). No motion segments in the Vitoss BA group (0/11) showed any signs of fusion. The SiCaP-30 group demonstrated a statistically higher manual palpation and motion analysis fusion rate of 82% (9/11; p<0.05) and produced superior bone formation compared with Actifuse ABX and βTCP-BG.
Details
- Title: Subtitle
- Assessment of SiCaP-30 in a Rabbit Posterolateral Fusion Model with Concurrent Chemotherapy
- Creators
- Joseph D Smucker - The University of Iowa, Department of Orthopaedics and Rehabilitation , Iowa City, Iowa ; The Bone Healing Research Laboratory; The Iowa Spine Research CenterEmily B Petersen - The University of Iowa, Department of Orthopaedics and Rehabilitation , Iowa City, Iowa ; The Bone Healing Research Laboratory; The Iowa Spine Research CenterAli Al-Hili - The University of Iowa, Department of Orthopaedics and Rehabilitation , Iowa City, Iowa ; The Bone Healing Research Laboratory; The Iowa Spine Research CenterJames V Nepola - The University of Iowa, Department of Orthopaedics and Rehabilitation , Iowa City, Iowa ; The Bone Healing Research Laboratory; The Iowa Spine Research CenterDouglas C Fredericks - The University of Iowa, Department of Orthopaedics and Rehabilitation , Iowa City, Iowa ; The Bone Healing Research Laboratory; The Iowa Spine Research Center
- Resource Type
- Journal article
- Publication Details
- The Iowa orthopaedic journal, Vol.35, pp.140-146
- PMID
- 26361457
- PMCID
- PMC4492144
- NLM abbreviation
- Iowa Orthop J
- ISSN
- 1541-5457
- eISSN
- 1555-1377
- Publisher
- Dept. of Orthopaedics, The University of Iowa; United States
- Language
- English
- Date published
- 2015
- Academic Unit
- Orthopedics and Rehabilitation; Craniofacial Anomalies Research Center
- Record Identifier
- 9984040467802771
Metrics
28 Record Views